Tackling the Opioid Epidemic

Opioid Use Disorder in Pregnancy: Where We Are, What We Know, What We Are Doing at UK

Activity Details
  • Credit Amounts:
    • CME: 0.75
    • Other: 0.75
  • Cost: Free
  • Release: Apr 15, 2017
  • Expires: Apr 14, 2020
  • Estimated Time to Complete:
    45 Minutes
  • System Requirements:
  • Average User Rating:
    (2 Ratings)

Faculty

Agatha S.  Critchfield Agatha S. Critchfield, MD
Assistant Professor, Obstetrics and Gynecology, Maternal Fetal Medicine
University of Kentucky College of Medicine
Medical Director, PATHways Program
UK HealthCare
Lexington, Kentucky

Needs Statement

Drug overdose is a huge problem facing the health care system in Kentucky. Drug overdose deaths are acute poisoning deaths due to prescription or illicit drugs. According to data from the National Center for Health Statistics, Kentucky had the second highest drug overdose death rate in the U.S. in 2013.

Kentucky Injury Prevention and Research Center - http://www.mc.uky.edu/kiprc/  
Kentucky Department for Public Health http://chfs.ky.gov/dph/  
Released October 2015 

žAs of 2012, 5.9% of pregnant women in US report illicit drug use and ž1.6% of pregnant women meet criteria for drug use disorder. Neonatal Abstinence Syndrome (NAS) increased 300% from 2000– 2009.

Target Audience

Healthcare professionals prescribing opiates interested in reducing addiction and discovering treatment options for addicted patients.

Objectives

Upon completion of this educational activity, participants will be able to:

  • Discuss current trends and consequences of Opioid Use Disorder in Pregnancy
  • Describe options and controversies in treatment during pregnancy
  • Discuss Neonatal Abstinence Syndrome
  • Describe current perinatal treatment options at UK: PATHways

Accreditation

CME
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Kentucky College of Medicine, and Kentucky Office of Drug Control Policy. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

This training has been approved by the KBML as meeting the statutory requirements of HB1.

ACGME Competencies

  • Patient care
  • Medical knowledge
  • Interpersonal and communication skills

Other
UK Healthcare CECentral certifies this activity for 0.75 hours of participation.

Faculty Disclosure

Michelle Lofwalll, MD (planner and speaker) has relevant financial relationships with commercial interests as follows:

  • Braeburn Pharmaceuticals - Consultant and Principal Investigator - Consulting Fees and Research Contract
  • PCM Scientific - Speaker - Honoraria

No speaker or other planners have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speaker. In some cases, the presentation might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. The speaker will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

This activity is jointly provided by the University of Kentucky and Kentucky Office of Drug Control Policy.

In collaboration with Kentucky Injury Prevention and Research Center University of Kentucky College of Public Health.